AZD 7594

Drug Profile

AZD 7594

Alternative Names: AZ13189620; AZD-7594

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Antiasthmatics; Small molecules
  • Mechanism of Action Glucocorticoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma
  • Phase I Chronic obstructive pulmonary disease

Most Recent Events

  • 06 Apr 2017 AstraZeneca completes a phase I trial for Chronic obstructive pulmonary disease and asthma (In voulnteers) in Germany (NCT02967159)
  • 21 Mar 2017 AstraZeneca completes enrolment in a phase I pharmacokinetics trial in Healthy volunteers in Germany (NCT02928354)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top